Akebia Therapeutics, Inc. (NASDAQ:AKBA) Shares Bought by Barclays PLC

Barclays PLC increased its stake in Akebia Therapeutics, Inc. (NASDAQ:AKBA - Free Report) by 276.1% in the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 273,085 shares of the biopharmaceutical company's stock after acquiring an additional 200,482 shares during the quarter. Barclays PLC owned approximately 0.13% of Akebia Therapeutics worth $360,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Mercer Global Advisors Inc. ADV grew its holdings in shares of Akebia Therapeutics by 40.7% during the second quarter. Mercer Global Advisors Inc. ADV now owns 31,221 shares of the biopharmaceutical company's stock worth $32,000 after buying an additional 9,037 shares in the last quarter. Empirical Asset Management LLC purchased a new stake in shares of Akebia Therapeutics during the third quarter worth $44,000. B. Riley Wealth Advisors Inc. purchased a new stake in shares of Akebia Therapeutics during the second quarter worth $44,000. XTX Topco Ltd purchased a new stake in shares of Akebia Therapeutics during the third quarter worth $58,000. Finally, Intech Investment Management LLC purchased a new stake in shares of Akebia Therapeutics during the third quarter worth $59,000. Hedge funds and other institutional investors own 33.92% of the company's stock.

Akebia Therapeutics Stock Performance

Shares of AKBA stock traded up $0.14 on Monday, hitting $2.07. 6,512,128 shares of the stock traded hands, compared to its average volume of 1,701,380. The firm's 50-day moving average price is $1.91 and its two-hundred day moving average price is $1.58. The stock has a market capitalization of $451.63 million, a PE ratio of -9.00 and a beta of 0.72. Akebia Therapeutics, Inc. has a twelve month low of $0.80 and a twelve month high of $2.48.

Akebia Therapeutics (NASDAQ:AKBA - Get Free Report) last announced its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.10) earnings per share for the quarter, missing the consensus estimate of ($0.04) by ($0.06). The firm had revenue of $37.43 million for the quarter, compared to analysts' expectations of $45.66 million. During the same quarter last year, the firm posted ($0.08) earnings per share. On average, equities research analysts anticipate that Akebia Therapeutics, Inc. will post -0.26 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on the stock. HC Wainwright reaffirmed a "buy" rating and set a $7.50 target price on shares of Akebia Therapeutics in a report on Tuesday, January 14th. StockNews.com cut shares of Akebia Therapeutics from a "hold" rating to a "sell" rating in a research report on Wednesday, January 15th.

Akebia Therapeutics Profile

Akebia Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients.